natgillin/translations-raw huggingface dataset:
Hos bedøvede kaniner udviste hydroxocobalamin en hæmodynamisk påvirkning (en forhøjelse af det gennnemsnitlige arterielle blodtryk og af den totale perifere modstand, et fald i minutvolumen), som er relateret til dets evne til at udskille nitrogenoxid.
In anaesthetised rabbits, hydroxocobalamin exerted haemodynamic effects (increased mean arterial blood pressure and total peripheral resistance, decreased cardiac output) related to its nitric oxide- scavenging property.
Hos behandlingserfarne patienter
In treatment-experienced patients
Hos behandlingsnaive patienter var de hyppigst indberettede bivirkninger, som blev anset for at have en mulig eller sandsynlig forbindelse til rilpivirinhydrochlorid og emtricitabin/tenofovirdisoproxilfumarat, kvalme (9%), svimmelhed (8%), unormale drømme (8%), hovedpine (6%), diarré (5%) og insomni (5%) (samlede data fra fase III kliniske studier C209 og C215, se pkt.
In treatment-naïve patients, the most frequently reported adverse reactions considered possibly or probably related to rilpivirine hydrochloride and emtricitabine/tenofovir disoproxil fumarate were nausea (9%), dizziness (8%), abnormal dreams (8%), headache (6%), diarrhoea (5%) and insomnia (5%) (pooled data from the Phase III clinical studies C209 and C215, see section 5.1).
Hos boceprevir- behandlede forsøgspersoner, der ikke opnåede vedvarende virologisk respons (SVR), og hvis prøver blev analyseret, blev post-baseline RAVer påvist hos 53 %.
In boceprevir-treated subjects who did not attain sustained virologic response (SVR) for whom samples were analyzed, 53% had post- baseline RAVs detected.
Hos både katte og hunde er de hyppigste bivirkninger lokale reaktioner på påføringsstedet, f.eks. forbigående kløe og i sjældne tilfælde fedtet pels og rødme af huden.
In both cats and dogs the most common side effects are local reactions at the site of application, such as temporary itchiness, and on rare occasions, greasy fur and redness of the skin.
Hos både unge og voksne blev det påvist, at Nimenrix var immunologisk non-inferiør i forhold til ACWY-PS-vaccinen, hvad angik vaccinerespons, som defineret ovenfor (Tabel 11).
In both adolescents and adults, Nimenrix was demonstrated to be immunologically non-inferior to the ACWY-PS vaccine in terms of vaccine response as defined above (Table 11).
Hos børn (i alderen 12 måneder til 17 år) skal dosis baseres på patientens legemsoverfladeareal (se Instructions for Use in Paediatric Patients, Mosteller Formula).
In paediatric patients (12 months to 17 years of age), dosing should be based on the patient’s body surface area (see Instructions for Use in Paediatric Patients, Mosteller1 Formula).
Hos børn (i alderen 6 år eller derover), der behandles for Crohns sygdom eller colitis ulcerosa, er den anbefalede dosis den samme som for voksne.
In children (6 years of age or older) treated for Crohn’s disease or ulcerative colitis, the recommended dose is the same as for adults.
Hos børn afhænger dosen af kropsvægten og varierer fra 100 mg to gange dagligt til 200 mg to gange dagligt.
In children, the dose depends on body weight and ranges from 100 mg twice a day to 200 mg twice a day.
Hos børn blev Invanz sammenlignet med ceftriaxon (ikke-hospitalserhvervet lungebetændelse, 389 børn) og ticarcillin/clavulanat (infektioner i maven, 105 børn).
In studies in children, Invanz was compared with ceftriaxone (community-acquired pneumonia, 389 children) and ticarcillin/clavulanate (intra- abdominal infections, 105 children).
Hos børn blev Prevenar 13’s evne til at udløse dannelse af antistoffer (immunogenicitet) vurderet i to hovedundersøgelser, der omfattede 1 266 raske børn, som blev vaccineret i alderen to til 15 måneder, samt i en tredje undersøgelse af 598 børn mellem fem og 17 år, der tidligere var blevet vaccineret med Prevenar, eller som aldrig var blevet vaccineret mod invasiv pneumokoksygdom.
In children, the ability of Prevenar 13 to trigger the production of antibodies (immunogenicity) was assessed in two main studies involving 1,266 healthy children who were vaccinated between the ages of two and 15 months and in a third study involving 598 children aged between five and 17 years old who had previously been vaccinated with Prevenar or who had never been vaccinated for invasive pneumococcal disease.
Hos børn bør det overvejes at øge dosis af lopinavir/ritonavir til 300/75 mg/m2 2 gange daglig sammen med mad når det co- administreres med Viramune, specielt hos patienter, hvor der er mistanke om en reduceret følsomhed for lopinavir/ritonavir.
For children, increase of the dose of lopinavir/ritonavir to 300/75 mg/m2 twice daily with food should be considered when used in combination with Viramune, particularly for patients in whom reduced susceptibility to lopinavir/ritonavir is suspected.
Hos børn bør det overvejes at øge dosis af lopinavir/ritonavir til 300/75 mg/m2 2 gange dagligt sammen med mad når det co- administreres med Viramune, specielt hos patienter, hvor der er mistanke om en reduceret følsomhed for lopinavir/ritonavir.
For children, increase of the dose of lopinavir/ritonavir to 300/75 mg/m2 twice daily with food should be considered when used in combination with Viramune, particularly for patients in whom reduced susceptibility to lopinavir/ritonavir is suspected.
Hos børn er de hyppigste bivirkninger (som optræder hos flere end 1 ud af 10 patienter) opkastning, hoste og nasal kongestion (stoppet næse).
In children the most common side effects (seen in more than 1 patient in 10) are vomiting, cough and nasal congestion (a blocked nose).
hos børn født i 35. gestationsuge eller yngre, og yngre end 6 måneder ved begyndelsen af RSV- sæsonen.
Children born at 35 weeks of gestation or less and less than 6 months of age at the onset of the RSV season
hos børn født i 35. gestationsuge eller yngre, og yngre end 6 måneder ved begyndelsen af RSV- sæsonen.
Children born at 35 weeks of gestation or less and less than 6 months of age at the onset of the RSV season.
Hos børn gav administration af tabletter højere lamivudin-plasma-AUC∞ og - Cmax end oral opløsning.
In children, administration of tablets delivered higher plasma lamivudine AUC∞ and Cmax than oral solution.
Hos børn gives to injektioner (med mindst to måneders mellemrum) bortset fra spædbørn mellem to og fem måneder, som skal have tre injektioner (med mindst en måneds mellemrum).
In younger children, two injections are given (at an interval of at least two months), except in infants aged between two and five months who receive three injections (at intervals of at least one month).
Hos børn havde 99 % til 100 % af børnene, der havde fået begge doser af Ixiaro, udviklet beskyttende antistofmængder fire uger efter den sidste injektion.
In children, four weeks after the final injection, 99% to 100 % of children who received both doses of Ixiaro had developed protective levels of antibodies.
Hos børn i alderen 12-23 måneder var immunresponset, som 2 doser fremkaldte, sammenligneligt med det respons, som 3 doser fremkaldte hos spædbørn i alderen under 6 måneder, undtagen for vaccineserotyperne 18C og 19F samt for serotype 19A, hvis respons var højere hos børn i 12-23 månedersalderen.
In children aged 12-23 months, the immune responses elicited after two doses were comparable to the responses elicited after three doses in infants below 6 months of age, except for vaccine serotypes 18C and 19F as well as serotype 19A for which responses were higher in the 12-23 months children.
Hos børn i alderen 2-5 år er de hyppigste bivirkninger tilstoppet næse (26,5 %), infektion i de øvre luftveje (23,5 %), forhøjet indhold af leverenzymer (14,7 %), udslæt (11,8 %) og bakterier i slimen (11,8 %).
In children aged 2 to 5 years the most common side effects are nasal congestion (26.5 %), upper respiratory tract infection (23.5 %), increase in liver enzymes (14.7 %), rash (11.8 %) and bacteria in sputum (11.8 %).
Hos børn i alderen 2-5 år, som fik 1 dosis, var ELISA-antistof-GMC sammenlignelig for 6 vaccineserotyper samt for serotype 19A i forhold til, hvad der blev opnået efter et 3-dosis vaccinationsprogram hos spædbørn i alderen under 6 måneder, mens de var lavere for 4 vaccineserotyper (serotype 1, 5, 14 og 23F).
In children aged 2 to 5 years that received 1 dose, the ELISA antibody GMCs were similar for 6 vaccine serotypes as well as serotype 19A than those achieved following a 3-dose vaccination schedule in infants below 6 months of age while they were lower for 4 vaccine serotypes (serotypes 1, 5, 14 and 23F).
Hos børn i alderen 3-11 år skal 'testmåltidet' bestå af 100 ml ren appelsinjuice.
In children aged three to 11 years, the ‘test meal’ should be 100 ml of pure orange juice.
Hos børn i alderen 6 til under 12 år var forekomsten af patienter, der oplevede aminotransferaseforhøjelser (ALAT eller ASAT) > 3 x ULN, 15,0 % (6/40) hos ivacaftor-behandlede patienter og 14,6 % (6/41) hos patienter, der fik placebo.
In children aged 6 to less than 12 years, the incidence of patients experiencing transaminase elevations (ALT or AST) >3 x ULN was 15.0% (6/40) in ivacaftor-treated patients and 14.6% (6/41) in patients who received placebo.
Hos børn i alderen 6 til under 12 år var forekomsten af patienter, der oplevede aminotransferaseforhøjelser (ALAT eller ASAT), > 3 x ULN, 15,0 % (6/40) hos ivacaftor-behandlede patienter og 14,6 % (6/41) hos patienter, der fik placebo.
In children aged 6 to less than 12 years, the incidence of patients experiencing transaminase elevations (ALT or AST) >3 x ULN was 15.0% (6/40) in ivacaftor-treated patients and 14.6% (6/41) in patients who received placebo.
Hos børn i alderen 6-17 år var bivirkningerne de samme som beskrevet herunder, dog med følgende undtagelser: lungebetændelse, væskemangel (dehydrering), nedsat svedproduktion (almindelig) og unormale prøver for leverfunktion (ikke almindelig), mellemørebetændelse, ondt i halsen, bihule- eller lungebetændelse, hose, næseblod, dryppende næse, mavepine, opkast, kløe, eksem og feber.
In children ages 6 – 17 years old, side effects were consistent with those described below with the following exceptions: pneumonia, dehydration, sweating decreased (common), abnormal liver enzymes (uncommon), middle ear infection, sore throat, sinus and chest infections, cough, nosebleeds, runny nose, stomach pain, vomiting, rash, eczema and fever.
Hos børn i alderen 6-17 år var bivirkningerne de samme som beskrevet herunder, dog med følgende undtagelser: lungebetændelse, væskemangel (dehydrering), nedsat svedproduktion (almindelig) og unormale prøver for leverfunktion (ikke almindelig).
In children ages 6 – 17 years old, side effects were consistent with those described below with the following exceptions: pneumonia, dehydration, sweating decreased (common) and abnormal liver enzymes (uncommon).
Hos børn i alderen to måneder til tre år bør der gives en halv voksendosis af Ixiaro (0,25 ml) efterfulgt af en yderligere dosis på 0,25 ml fire uger senere.
In children aged between two months and three years, half the adult dose of Ixiaro (0.25 ml) should be given, and an additional 0.25 ml dose should be given four weeks later.
Hos børn i aldersgrupperne 3-5 år og 6-9 år, som fik enten to fulde doser eller to halve doser AS03- adjuveret vaccine indeholdende 3,75 μg HA fra A/Vietnam/1194/2004 (H5N1), var anti-HA- antistofresponset mod A/Indonesia/5/2005 på dag 42 følgende:
In the subjects aged 3 to 5 and 6 to 9 years old who received two doses of either a full or a half dose of AS03-adjuvanted vaccine containing 3.75 µg HA derived from A/Vietnam/1194/2004 (H5N1), the anti-HA antibody responses against A/Indonesia/5/2005 at day 42 were as follows:
hos børn i hæmodialyse
in children on haemodialysis
Hos børn kan endvidere ses følgende bivirkninger
Additional side effects in children
Hos børn med diabetes, skal monitorering af blodsukkeret øges.
In children with diabetes, blood glucose monitoring should be increased.
Hos børn med ITP er den anbefalede startdosis 25 mg en gang dagligt til børn i alderen 1-5 år og 50 mg til børn i alderen 6-17 år, undtagen hos patienter af østasiatisk oprindelse (f.eks. japanere, kinesere, taiwanere eller koreanere), hvor dosis bør være 25 mg en gang dagligt.
In children with ITP, the daily recommended dose is 25 mg for children aged 1 to 5 years, and 50 mg for children aged 6 to 17 years, except in patients of East Asian descent (such as Japanese, Chinese, Taiwanese or Korean) where it should be 25 mg once a day.
Hos børn med kronisk hepatitis C blev virkningen af 48 ugers behandling med Pegasys og ribavirin undersøgt hos 55 børn i én hovedundersøgelse.
In children with chronic hepatitis C, the effectiveness of 48 weeks of treatment with Pegasys and ribavirin was examined in 55 children in one main study.
Hos børn med kronisk ITP blev Revolade sammenlignet med placebo i en hovedundersøgelse, hvori der deltog i alt 92 børn mellem 1 og 17 år, som tidligere var blevet behandlet for ITP.
In children with chronic ITP, Revolade was compared with placebo in one main study involving a total of 92 children between 1 and 17 years of age who had previously received treatment for ITP.
Hos børn mellem 2 måneder og <3 år er følgende bivirkninger observeret oftere end hos børn i alderen mellem 3 og < 12 år, teenagere og voksne:
In children aged 2 months to <3 years, the following side effects have been observed more frequently compared to children aged 3 years to <12 years, adolescents and adults:
Hos børn mellem 6 måneder og 12 år gives Emend som oral suspension sammen med en 5-HT3- antagonist.
In children between 6 months and 12 years of age, Emend oral suspension is given together with a 5- HT3 antagonist.
Hos børn mellem et og seks år blev sygdommens varighed gennemsnitligt afkortet med 1,5 dag.
The average reduction in the duration of the disease in children aged one to six years was 1.5 days.
Hos børn og teenagere kan endvidere ses følgende bivirkninger:
Additional side effects in children and adolescents
Hos børn og unge er dosis
In children and adolescents, the dose is
Hos børn og unge kan Imatinib Accord dog anvendes til behandling af alle stadier af sygdommen.
In children and adolescents however it may be used to treat all stages of the illness.
Hos børn og unge med aids kan lægemidlet bruges til at forhindre generende infektioner.
Children and adolescents with the Acquired Immune Deficiency Syndrome (AIDS), it can be used to prevent troublesome infections.
Hos børn og unge patienter behandlet med Ribavirin Teva Pharma B.V. plus interferon alfa-2b, reduceres ribavirin-dosis til 7,5 mg/kg/dag.
In children and adolescent patients treated with Ribavirin Teva Pharma B.V. plus interferon alfa-2b, reduce ribavirin dose to 7.5 mg/kg/day.
Hos børn og unge patienter er 1. dosisreduktion af ribavirin til 12 mg/kg/dag, 2. dosisreduktion af ribavirin er til 8 mg/kg/dag.
In children and adolescent patients 1st dose reduction of ribavirin is to 12 mg/kg/day, 2nd dose reduction of ribavirin is to 8 mg/kg/day.
Hos børn og unge patienter, der fik legemsoverflade-justeret dosering af ViraferonPeg med 60 μg/m2/uge, forudses det log-transformerede ratioestimat af eksponering i doseringsintervallet at være 58 % (90 % CI: 141-177 %) højere end observeret hos voksne, der fik 1,5 μg/kg/uge.
In children and adolescent patients receiving body surface area-adjusted dosing of ViraferonPeg at 60 µg/m2/week, the log transformed ratio estimate of exposure during the dosing interval is predicted to be 58 % (90 % CI: 141-177 %) higher than observed in adults receiving 1.5 µg/kg/week.
Hos børn og unge patienter, der fik legemsoverflade-justeret dosering af ViraferonPeg med 60 μg/m2/uge, forudses det log-transformerede ratioestimat af eksponering i doseringsintervallet at være 58 % (90 % CI: 141-177 %) højere end observeret hos voksne, der fik 1,5 μg/kg/uge..
In children and adolescent patients receiving body surface area-adjusted dosing of ViraferonPeg at 60 g/m2/week, the log transformed ratio estimate of exposure during the dosing interval is predicted to be 58 % (90 % CI: 141-177 %) higher than observed in adults receiving 1.5 g/kg/week.
Hos børn og unge reduceres PegIntron 1. gang til 40 μg/m2/uge, 2. dosisreduktion af PegIntron er til 20 μg/m2/uge.
In children and adolescent patients 1st dose reduction of PegIntron is to 40 µg/m2/week, 2nd dose reduction of PegIntron is to 20 µg/m2/week.
Hos børn og unge reduceres PegIntron 1. gang til 40 μg/m2/uge, 2. dosisreduktion af PegIntron er til 20 μg/m2/uge.
In children and adolescent patients 1st dose reduction of PegIntron is to 40 g/m2/week, 2nd dose reduction of PegIntron is to 20 g/m2/week.
Hos børn og unge reduceres ViraferonPeg 1. gang til 40 μg/m2/uge, 2. dosisreduktion af ViraferonPeg er til 20 μg/m2/uge.
In children and adolescent patients 1st dose reduction of ViraferonPeg is to 40 g/m2/week, 2nd dose reduction of ViraferonPeg is to 20 g/m2/week.
Hos børn og unge, som tager TNF-blokerende midler, har der været tilfælde af kræft, herunder usædvanlige typer, som undertiden har været dødelige (se nedenfor under "Børn og unge").
There have been cases of cancers, including unusual types, in children and teenage patients taking TNF-blocking agents, which sometimes resulted in death (see further down “Children and adolescents”).
Hos børn og voksne anvendes det kun til dem, der ikke kan behandles med nukleotid reverse transkriptasehæmmere (NRTI) som førstevalgsbehandling.
In children and adolescents its use is only for those who cannot be treated with other first-line nucleotide reverse transcriptase inhibitors (NRTI).
Hos børn op til 17-års-alderen varierer den anbefalede dosis af Busulfan Fresenius Kabi mellem 0,8 og 1,2 mg pr. kg, afhængigt af barnets vægt.
In children up to 17 years of age, the recommended dose of Busulfan Fresenius Kabi varies between 0.8 and 1.2 mg per kilogram depending on the weight of the child.
Hos børn på 1 år og derover starter behandlingen med STAYVEER sædvanligvis med 2 mg pr. kg legemsvægt to gange dagligt (morgen og aften).
For children 1 year and older, treatment with STAYVEER is usually started with 2 mg per kg bodyweight twice daily (morning and evening).
Hos børn på 1 år og derover starter behandlingen med Tracleer sædvanligvis med 2 mg pr. kg legemsvægt to gange dagligt (morgen og aften).
For children 1 year and older, treatment with Tracleer is usually started with 2 mg per kg bodyweight twice daily (morning and evening).
Hos børn på et år og derover med pulmonal arteriel hypertension er den anbefalede startdosis og vedligeholdelsesdosis 2 mg pr. kg legemsvægt to gange dagligt.
In children with PAH aged 1 year and older, the recommended starting and maintenance dose is 2 mg per kilogram body weight twice a day.
Hos børn svarede virkningen til sammenligningsstoffernes og til virkningen hos voksne.
In children, its effectiveness was comparable to that of the comparators, and to the effectiveness seen in adults.
Hos børn udviste Revestive lignende effektivitetsresultater og sikkerhedsprofil, hvilket underbygger anvendelsen af Revestive hos disse patienter.
Similar efficacy results and safety profile were seen in children, supporting the use of Revestive in these patients.
Hos børn under 10 år er den daglige dosis 100 mg/kg/dag fordelt på 2 doser.
In children less than 10 years of age, the daily dose is 100 mg/kg/day given in 2 doses.
Hos børn under 18 år er der en mulig sammenhæng mellem ASA og Reyes syndrom.
In children under 18 years of age, there is a possible association between ASA and Reye’s syndrome.
Hos børn under tre år var feber, diarré, influenzalignende sygdom, irritabilitet og rødme på injektionsstedet de hyppigste bivirkninger (som optræder hos flere end ét ud af 10 børn), og hos børn i alderen tre år og derover var de hyppigste bivirkninger smerter og ømhed på injektionsstedet.
In children aged less than 3 years, fever, diarrhoea, influenza-like illness, irritability and redness at injection site were the most common side effects (seen in more than 1 of 10 children) and in children aged 3 years and older, fever and injection site pain and tenderness were most common.
Hos børn, der er blevet vaccineret i småbørnsalderen, blev persistensen af immunresponset vurderet ved rSBA og hSBA i studierne MenACWY-TT-048 og MenACWY-TT-032 samt henholdsvis i op til 4 år efter vaccination i studie MenACWY-TT-039 (tabel 5) og i op til 5 år efter vaccination i studie MenACWY-TT-027 (tabel 5).
In children primed at toddler age, the persistence of the immune response was evaluated by rSBA and hSBA in studies MenACWY-TT-048 and MenACWY-TT-032, up to 4 years after priming in study MenACWY-TT-039 (Table 5) and up to 5 years after priming in study MenACWY-TT-027 (Table 6) respectively.
Hos børn, der er blevet vaccineret i småbørnsalderen, blev persistensen af immunresponset vurderet ved rSBA og hSBA i studierne MenACWY-TT-048 og MenACWY-TT-032 samt henholdsvis i op til 4 år efter vaccination i studie MenACWY-TT-039 (tabel 5) og i op til 5 år efter vaccination i studie MenACWY-TT-027 (tabel 6).
In children primed at toddler age, the persistence of the immune response was evaluated by rSBA and hSBA in studies MenACWY-TT-048 and MenACWY-TT-032, up to 4 years after priming in study MenACWY-TT-039 (Table 5) and up to 5 years after priming in study MenACWY-TT-027 (Table 6) respectively.
Hos børn, der over over 40 kg, skal den samlede injektionsvolumen derfor deles i lige dele mellem to injektionssteder, da det vil være nødvendigt med mere end 1 ml suspension.
Therefore, in children weighing more than 40 kg the overall injection volume must be divided into equal parts between two injection sites, as more than 1 mL of suspension is required.
Hos børn, der vejer mindre end 35 kg, er den anbefalede dosis 20 mg, der gives som to doser på 10 mg.
In children weighing less than 35 kg, it is 20 mg, given as two 10 mg doses.
Hos børn, der vejer under 14 kg, er den anbefalede dosis 50 mg to gange dagligt.
For children weighing less than 14 kg the recommended dose is 50 mg twice a day.
Hos børn, hvis mødre tog nucleosid-revers transkriptasehæmmeres (NRTI’er) under graviditeten, opvejede fordelen ved beskyttelse mod hiv risikoen for bivirkninger.
In children whose mothers took nucleoside reverse transcriptase inhibitors (NRTIs) during pregnancy, the benefit from the protection against HIV outweighed the risk of side effects.
Hos børnene i undersøgelsen havde 51,5 % (52 ud af 101) et virusindhold på under 50 kopier/ml efter at have fået Intelence i 24 uger, og dette steg lidt efter 48 uger.
In children, 51.5% (52 out of 101) of the study participants had a viral load below 50 copies/ml after 24 weeks of taking Intelence, and this was slightly increased after 48 weeks.
Hos C/C-patienter der fik tre- stofbehandling havde 89 % behandlingsnaive ikke-detekterbart hcv-RNA ved behandlingsuge 8 og var
In C/C patients receiving tritherapy 89% in treatment naive were HCV-RNA undetectable by TW 8 and eligible for shorter duration of therapy as compared to 52% in treatment naïve non C/C.
Hos ca. halvdelen af patienterne fandtes organinvolvering i tre eller flere organer, primært i form af spredning til lungerne (74 %) og/eller til lymfeknuderne (54 %).
Approximately half of all patients had 3 or more organs involved in their disease and most patients had the lung (74 %), and/or lymph nodes (54 %) as a metastatic location for disease at baseline.
Hos cancerpatienter
In cancer patients
Hos CAPS- patienter har der været bemærket en tilnærmet dosislinearitet med en let tendens til en mere end proportional stigning.
In CAPS patients approximate dose linearity with a slight tendency to higher than proportional increase has been noted.
Hos cirrosepatienter med svagt nedsat leverfunktion (klassificeret som Child-Pugh A) sås der kun mindre ændringer i rivaroxabans farmakokinetik (gennemsnitlig stigning i AUC for rivaroxaban på 1,2 gange), hvilket næsten er sammenligneligt med den tilsvarende raske kontrolgruppe.
Cirrhotic patients with mild hepatic impairment (classified as Child Pugh A) exhibited only minor changes in rivaroxaban pharmacokinetics (1.2 fold increase in rivaroxaban AUC on average), nearly comparable to their matched healthy control group.
Hos collier og beslægtede racer skal man være omhyggelig med at overholde den anbefalede dosis.
The recommended dose should be strictly observed in collies or related breeds.